PTHR10373: Difference between revisions

From GO Wiki
Jump to navigation Jump to search
Line 18: Line 18:
*Based on the definition, shouldn't GO:0003705 "sequence-specific enhancer binding RNA polymerase II transcription factor activity" have some sort of relationship, either is_a or has_part, GO:0035326 "enhancer binding"?
*Based on the definition, shouldn't GO:0003705 "sequence-specific enhancer binding RNA polymerase II transcription factor activity" have some sort of relationship, either is_a or has_part, GO:0035326 "enhancer binding"?
==Biological Process==
==Biological Process==
*The term GO:0071899 "negative regulation of estrogen receptor binding" is defined as "Any process that stops, prevents, or reduces the frequency, rate or extent of estrogen receptor binding, interacting selectively with an estrogen receptor."  Binding to what?  So, if protein X is annotated to 71899, does it mean that it prevents some other protein Y from binding to the estrogen receptor?  If so, should protein Y be listed in the "with" column?  Alternatively, does it mean that X prevents the estrogen receptor from binding DNA?  Should those two scenarios (binding DNA vs. binding a protein) be separated into new child terms?  Is this a general problem with all the "regulation of protein binding" terms?
*The term GO:0071899 "negative regulation of estrogen receptor binding" is defined as "Any process that stops, prevents, or reduces the frequency, rate or extent of estrogen receptor binding, interacting selectively with an estrogen receptor."  Binding to what?  So, if protein X is annotated to 71899, does it mean that it prevents some other protein Y from binding to the estrogen receptor?  If so, should protein Y be listed in the "with" column?  Alternatively, does it mean that X prevents the estrogen receptor from binding DNA?  Should those two scenarios (binding DNA vs. binding a protein) be separated into new child terms?  Is this a general problem with all the "regulation of ___ binding" terms?

Revision as of 13:53, 5 August 2011

This is a list of questions that arose while PAINTing PTHR_____.

Questions for MOD curators

Molecular Function

Human LEF1

  • Question: Is the IMP to GO:0043027 "caspase inhibitor activity" in PMID 20360943 appropriate? Does the experiment really show a biochemical interaction between LEF1 and caspase, or is reduction of caspase activity aresult of mutating LEF1? If the latter, shouldn't that be a BP annotation?
    • Curator answer: Insert answer here.
  • Question: Does LEF1 really bind estrogen, as the GO:0030284 "estrogen receptor activity" IDA from PMID 18794125 implies? How could LEF1 have both "estrogen receptor activity" and "estrogen receptor binding" activity (from the same paper)?
    • Curator answer: Insert answer here.

Organism(s) 2

Cellular Component

Biological Process

Questions for ontology curators

Molecular Function

  • Based on the definition, shouldn't GO:0003705 "sequence-specific enhancer binding RNA polymerase II transcription factor activity" have some sort of relationship, either is_a or has_part, GO:0035326 "enhancer binding"?

Biological Process

  • The term GO:0071899 "negative regulation of estrogen receptor binding" is defined as "Any process that stops, prevents, or reduces the frequency, rate or extent of estrogen receptor binding, interacting selectively with an estrogen receptor." Binding to what? So, if protein X is annotated to 71899, does it mean that it prevents some other protein Y from binding to the estrogen receptor? If so, should protein Y be listed in the "with" column? Alternatively, does it mean that X prevents the estrogen receptor from binding DNA? Should those two scenarios (binding DNA vs. binding a protein) be separated into new child terms? Is this a general problem with all the "regulation of ___ binding" terms?